Nanasonics has released there FY2021 results, key highlights include:

- Revenue 103.1m - up 3% (or 12% in constant currency).
- Second half revenue 60m (up 60% in constant currency).

- Earnings before interest and tax 10.7m (down 7.8%)
- USA total addressable market revised from 40K to 60K Trophon units
- Consumable and service revenue of 42.7m (up 27% compared to first half)
- Cash & cash equivilence 96m
 

Although, the initial results read poorly (with only 3% revenue growth and EBIT down 7.8%). There, were some positives coming out of the report with the announcement of a new product platform - Nanasonics Coris which sounds like it is a decontamination device for disinfecting endoscopes.

This device would fit in line well with the Trophon product which disinfects ultrasound probes for early stage pregnancy.

My assumption is both products would have a similar "razor blade" model with recurring revenue for disenfectant consumables.

With PE over 200x it is difficult to give it a buy. I do own shares in my strawman & real portfolio but purchased around the $2.50, I would like to add more at a more reasonable multiple.